Stocks Health care IQV
NYSE · Health careIqvia Holdings Inc. (IQV)
Iqvia Holdings Inc. brought in $17.3B of revenue over the twelve months to September 30, 2026, up 8.8% from a year earlier. Net income was $1.4B, a net margin of 8.1%. Operating cash flow minus capital spending left $2.1B of free cash flow in fiscal 2025. At September 30, 2026 it held $2.2B in cash against $16.1B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 27, 2026.
Key facts about Iqvia Holdings Inc.
- Net worth
- Iqvia Holdings Inc. has a market value (market cap) of $45.9B at the latest share price, and shareholders' equity of $6.7B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $16.3B (+5.9% year on year), with net income of $1.4B. Over the 12 months to September 30, 2026: revenue $17.3B, net income $1.4B.
- Cash flow
- In fiscal 2025 operations brought in $2.7B of cash; after $603M of capital spending, free cash flow was $2.1B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 27, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Iqvia Holdings Inc.'s next report is expected around February 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Iqvia Holdings Inc. does
IQVIA provides clinical research services, healthcare data analytics, and consulting services to pharmaceutical, biotechnology, and medical device companies. The company manages clinical trials for new drugs and licenses healthcare market data and commercial software to life sciences organizations. Its shares trade on NYSE under the ticker IQV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $16.3B | $1.4B | $7.84 | $2.1B |
| 2024 | $15.4B | $1.4B | $7.49 | $2.1B |
| 2023 | $15B | $1.4B | $7.29 | $1.5B |
| 2022 | $14.4B | $1.1B | $5.72 | $1.6B |
| 2021 | $13.9B | $966M | $4.95 | $2.3B |
| 2020 | $11.4B | $279M | $1.43 | $1.3B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IQV ranks in Health care
Dividends
It paid out $567.9M in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2013 | n/a | $567.9M | n/a |
| 2011 | n/a | $288.3M | n/a |
Latest SEC filings
What Iqvia Holdings Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 8% to $4.4B versus the same quarter last year; diluted EPS $2.10 versus $1.93.
- October 27, 2026
- September 23, 2026Material agreement8-KIQVIA subsidiary completed the issuance of $2,000,000,000 of 6.375% senior notes due 2034.
- September 9, 2026Other event 8-K
- July 28, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 8.7% to $4.4B versus the same quarter last year; diluted EPS $1.53 versus $1.54.
- July 28, 2026
- June 11, 2026
- June 4, 2026Other event 8-K
- June 3, 2026Other event 8-K
- May 7, 2026Other event 8-K
What is IQV worth? A DCF from its reported cash flow
Insider trades
What the people running Iqvia Holdings Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $697.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Berkshire James G.See Remarks | Exercised options | 5,381 | $709.3K |
| September 2, 2026 | Berkshire James G.See Remarks | Sold | 2,668 | $697.2K |
| September 2, 2026 | Berkshire James G.See Remarks | Other change | 2,713 | $709.6K |
| August 3, 2026 | Staub W RichardSee Remarks | Sold | 5,500 | $1.3M |
| July 31, 2026 | Patel BhavikSee Remarks | Sold | 1,855 | $436.4K |
| July 29, 2026 | Bousbib AriSee Remarks, Director | Exercised options | 156,206 | $12.2M |
| July 29, 2026 | Bousbib AriSee Remarks, Director | Sold | 4,465 | $1.1M |
| July 29, 2026 | Bousbib AriSee Remarks, Director | Sold | 4,584 | $1.1M |
Who owns IQV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.49% | April 30, 2026 |
| Harris Associates L P13G, passive with 1 related filers | 6.8% | August 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,087 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 14,549,693 | -477,751 |
| Harris Associates L P | 12,183,830 | +555 |
| Vanguard Capital Management LLC | 10,905,053 | -121,930 |
| State Street Corp | 7,508,244 | +31,282 |
| Vanguard Portfolio Management LLC | 7,501,993 | -74,008 |
| Jpmorgan Chase & Co | 6,139,775 | +732,085 |
| Artisan Partners Limited Partnership | 4,743,434 | -315,431 |
| Boston Partners | 4,466,016 | +227,058 |
| Geode Capital Management, LLC | 4,454,134 | -8,918 |
| Invesco Ltd. | 3,275,141 | +13,363 |
| Morgan Stanley | 2,707,252 | +97,385 |
| Norges Bank | 2,264,944 | new |
| Franklin Resources Inc | 2,105,185 | +1,600,943 |
| Goldman Sachs Group Inc | 1,949,797 | +772,517 |
| Dimensional Fund Advisors LP | 1,735,452 | +77,756 |
| Northern Trust Corp | 1,709,161 | -20,835 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,634,264 | +134,997 |
| Aqr Capital Management LLC | 1,536,874 | +296,016 |
| Longview Partners (Guernsey) LTD | 1,500,760 | -396,714 |
| Charles Schwab Investment Management Inc | 1,484,047 | +71,900 |
Insiders
14 insiders reported holding 1,054,403 shares in total, about $294M at the last price.
| Holder | Shares |
|---|---|
| Bousbib AriSee Remarks, Director | 835,941 |
| Bruehlman Ronald ESee Remarks | 44,103 |
| Danhakl John GDirector | 30,61230,612 held indirectly |
| Haas BerndSee Remarks | 24,394 |
| Grenfell AlistairSee Remarks | 24,124 |
| Sherbet EricSee Remarks | 20,999 |
| Leonard John MDirector | 16,946 |
| Goggins Colleen ADirector | 14,453 |
| Staub W RichardSee Remarks | 13,312 |
| Fedock Michael J.See Remarks | 9,472 |
Questions about IQV
What does Iqvia Holdings Inc. do?
IQVIA provides clinical research services, healthcare data analytics, and consulting services to pharmaceutical, biotechnology, and medical device companies. The company manages clinical trials for new drugs and licenses healthcare market data and commercial software to life sciences organizations. Its shares trade on NYSE under the ticker IQV.
What is Iqvia Holdings Inc.'s net worth?
Iqvia Holdings Inc. has a market value (market cap) of $45.9B at the latest share price, and shareholders' equity of $6.7B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Iqvia Holdings Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $1.4B on revenue of $17.3B, a net margin of 8.1%.
How much revenue does Iqvia Holdings Inc. make?
Over the twelve months to September 30, 2026 Iqvia Holdings Inc. reported revenue of $17.3B. That is 8.8% more than a year earlier.
When did Iqvia Holdings Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 27, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.
When is Iqvia Holdings Inc.'s next earnings report?
Iqvia Holdings Inc.'s next report is expected around February 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IQV with
Follow IQV
Get an email when Iqvia Holdings Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Iqvia Holdings Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.